CBS News finds clinicians promoting unapproved retatrutide online

A CBS News investigation published June 8, 2026, found that some doctors and nurses in the United States are promoting and prescribing retatrutide, an experimental weight-loss drug that has not been approved by the Food and Drug Administration.^[1] Reporters identified more than 120 websites and over 50 clinics across the country actively selling or promoting the unapproved medication.^[2]

Some of those operations are anonymous online vendors, but many are staffed by licensed physicians and nurse practitioners who argue the clinical trial evidence is already strong enough to skip the normal regulatory timeline.^[2] One provider named in the reporting, Jack Mutnick of Renew Med Spa Plus, said he is confident in Eli Lilly's trial results and believes patients should not have to wait for a government sign-off.^[2]

What retatrutide is, and where it stands

Retatrutide is an investigational triple hormone receptor agonist. It acts on the GIP, GLP-1 and glucagon receptors, a combination designed to blunt appetite while also increasing energy expenditure and fat breakdown.^[2] That is a step beyond semaglutide (Ozempic, Wegovy, Rybelsus), which targets GLP-1, and tirzepatide (Mounjaro, Zepbound), which targets GIP and GLP-1.

The phase 3 TRIUMPH-1 trial reported an average weight loss of 28.3% over 80 weeks at the 12 mg dose, with nearly half of participants losing 30% or more of their body weight.^[2] Those numbers explain the demand. But the drug remains strictly investigational: a regulatory submission is not expected until late 2026, and a market launch is considered unlikely before early 2028.^[2]

How sellers work around the law

The FDA has said retatrutide cannot legally be used in compounding, because it is not a component of any FDA-approved drug.^[2] To work around that, some sellers ship vials labeled "for research purposes only" or "not for human consumption" — labeling meant to shield the seller from liability even as the product is distributed for human use along with dosing instructions.^[2]

That means what is in the vial has not been checked by anyone. Risks include unknown ingredients, contaminants, and incorrect concentrations of the active drug.^[2] Pharmacists were also urged to watch for quality problems such as products that arrive warm or poorly refrigerated, which can degrade the medicine.^[2]

Harm signals are already appearing. Human exposures to retatrutide reported to US poison centers rose 265% in the first four months of 2026 compared with the end of 2025.^[2] Longer-term questions that normally get answered during regulatory review — thyroid C-cell tumors, pancreatitis, and treatment-emergent psychiatric events such as depression and suicidal ideation — remain open.^[2]

"Experimental drugs that have not yet been approved do not have the same level of evidence or oversight," said Jennifer Goldman, PharmD, a professor of pharmacy practice at the Massachusetts College of Pharmacy and Health Sciences. "When patients obtain unapproved products, they are accepting risks that are often not fully understood."^[2]

Why it matters for patients

A prescription pad or a clinic website does not change a drug's legal status. The sources describe licensed clinicians selling a product that has never cleared FDA review anywhere, sourced through research-chemical channels rather than a regulated supply chain.^[2] For a patient, that means no verified purity, no verified dose, no approved labeling, and no adverse-event monitoring system behind the product.

It also matters because the headline efficacy numbers are real. TRIUMPH-1's 28.3% average weight loss is the draw, and it came from a controlled trial with screening, dose escalation and safety monitoring — conditions that do not apply to a vial bought from a website.^[2]

Pharmacists are described as being positioned to assess eligibility for approved therapies and to flag quality problems.^[2] The reporting states that the only legal route to retatrutide right now is enrollment in a clinical trial.^[2]

What happens next

A regulatory submission for retatrutide is not anticipated until late 2026, with a launch projected no earlier than early 2028.^[2] Whether federal or state authorities take enforcement action against the clinics and websites identified by CBS News is not described in these sources. Details of any litigation by Eli Lilly against sellers are also not covered in the sources available here.